The impact of androgen ablation therapy on cognition in*

描述（由申请人提供）： 前列腺癌是美国男性中最常见的癌症部位，2004年有超过230，000名男性被诊断患有前列腺癌。这种疾病通常影响老年人; 70%的新病例发生在65岁以上的男性中。雄激素消融治疗是晚期前列腺癌的标准治疗方法。对于患有晚期疾病的男性，这种治疗的中位时间长度为2至5年。这种疗法对生活质量的影响已经有了很好的记录;然而，这种治疗对认知功能的影响尚未完全阐明。认知功能对独立性和生产力至关重要。直到最近，研究人员才发表了关于雄激素消融治疗对认知影响的研究。虽然这些研究提供了有价值的初步结果，表明雄激素消融可能会对记忆，视觉空间能力，心理速度和执行功能产生不利影响，但这些研究数量有限，并且没有产生一致的结果。这些研究主要针对仅接受雄激素消融治疗6至12个月的男性，但大多数晚期前列腺癌男性将继续接受雄激素消融治疗超过2年。此外，这些研究并没有特别关注65岁及以上的患者，这是最常患前列腺癌的人群。 本提案旨在通过进行一项比较研究来解决文献中的这些差距，该研究将比较75名65岁及以上晚期前列腺癌男性接受雄激素消融治疗2年的认知功能与75名尚未开始雄激素消融治疗的晚期前列腺癌男性的认知功能。这项研究的具体目标是： 1.确定接受雄激素阻断治疗2年的65岁以上男性的认知障碍领域。 2.确定接受雄激素消融治疗2年的65岁以上男性的认知障碍严重程度。

DESCRIPTION (provided by applicant): Prostate cancer is the most common site of cancer in men in the United States with over 230,000 men diagnosed with prostate cancer in 2004. This disease generally impacts older adults; 70% of all new cases occur in men greater than 65 years of age. Androgen ablation therapy is the standard treatment for advanced prostate cancer. For men with advanced stage disease, the median length of time on this treatment ranges from 2 to 5 years. The quality of life implications of this therapy have been well documented; however the impact of this treatment on cognitive functioning has not been fully elucidated. Cognitive functioning is vital for independence and productivity. Only recently have researchers published studies focusing on the cognitive impact of androgen ablation therapy. Although these studies have provided valuable preliminary results suggesting that androgen ablation may adversely affect memory, visuospatial abilities, psychomotor speed, and executive functioning, these studies are limited in number and have not produced consistent findings. These studies have focused on men who have been receiving androgen ablation therapy for only 6 to 12 months, however most men with advance stage prostate cancer will continue on androgen ablation for over 2 years. Additionally, these studies have not specifically focused on patients age 65 and older, the population most commonly afflicted with prostate cancer. This proposal seeks to address these gaps in the literature by conducting a comparison study that will compare the cognitive functioning of 75 men with late stage prostate cancer age 65 and older who have received androgen ablation therapy for 2 years to the cognitive functioning of 75 men with late stage prostate cancer who have not yet started androgen ablation therapy. The specific aims of this study are: 1. To determine the domains of cognitive impairment in men over the age of 65 who have received androgen ablation therapy for 2 years. 2. To determine the severity of cognitive impairment in men over the age of 65 who have received androgen ablation therapy for 2 years.